Johnson & Johnson (JNJ) PT Set at $147.00 by Cowen and Company

Cowen and Company set a $147.00 price target on Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Friday morning. The firm currently has a buy rating on the stock.

JNJ has been the topic of a number of other research reports. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an overweight rating in a report on Wednesday, July 5th. UBS AG reissued a buy rating and set a $148.00 target price on shares of Johnson & Johnson in a research note on Thursday, August 31st. BidaskClub downgraded shares of Johnson & Johnson from a strong-buy rating to a buy rating in a research note on Saturday, July 1st. Zacks Investment Research downgraded shares of Johnson & Johnson from a hold rating to a sell rating in a research note on Wednesday, September 27th. Finally, Jefferies Group LLC reissued a hold rating and set a $140.00 target price on shares of Johnson & Johnson in a research note on Friday, June 16th. Five investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $135.45.

Shares of Johnson & Johnson (NYSE JNJ) opened at 133.45 on Friday. The firm’s 50 day moving average is $132.26 and its 200 day moving average is $129.97. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company has a market cap of $358.18 billion, a PE ratio of 22.58 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.74 earnings per share. On average, equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) PT Set at $147.00 by Cowen and Company” was originally reported by BBNS and is the property of of BBNS. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://baseballnewssource.com/markets/johnson-johnson-jnj-pt-set-at-147-00-by-cowen-and-company/1703365.html.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.52%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of JNJ. Lynch & Associates IN grew its holdings in shares of Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after buying an additional 841 shares during the last quarter. Oakbrook Investments LLC grew its holdings in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after buying an additional 9,375 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $1,731,000. Bollard Group LLC grew its holdings in shares of Johnson & Johnson by 5.0% during the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after buying an additional 459 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. grew its holdings in shares of Johnson & Johnson by 278.0% during the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after buying an additional 177,900 shares during the last quarter. 65.90% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.

 


Latest News

Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley


Leave a Reply

 
© 2006-2017 BBNS.